Two drugmakers that produce the abortion pill mifepristone filed emergency requests with the Supreme Court on Saturday, asking the justices to freeze a Fifth Circuit ruling that cut off telehealth prescriptions and mail-order delivery of the drug nationwide. The filings landed just one day after the appeals court reinstated in-person dispensing requirements, and the companies say the decision is already sowing confusion among pharmacies, providers, and patients.
Danco Laboratories, which manufactures the brand-name version of mifepristone, and GenBioPro, which produces a generic, each filed separate applications. Both asked the court to immediately pause the lower-court order while the broader legal fight continues. The emergency requests were directed to Justice Samuel Alito, who handles matters arising from the Fifth Circuit and can act alone or refer the matter to the full court, Fox News Digital reported.
The speed of the filings signals how high the stakes are, not just for the abortion industry, but for the question of who ultimately controls pharmaceutical regulation in the United States. The Fifth Circuit's ruling effectively restored requirements that mifepristone be prescribed and dispensed in person by a medical provider, blocking the relaxed access rules the FDA had put in place in recent years. Those relaxed rules had allowed the drug to be prescribed via telehealth and shipped through the mail.
The appeals court found that Louisiana was likely to succeed in its challenge under the Administrative Procedure Act and applied the ruling nationwide. That last detail matters. The Supreme Court's 2025 decision in the CASA case had limited the reach of nationwide injunctions, but the Fifth Circuit concluded that its order should still apply across the country, Newsmax reported.
The practical effect: pharmacies can no longer distribute mifepristone under the challenged FDA rules, and doctors cannot prescribe it over a video call or send it by mail. Women must obtain the drug in person from a medical provider.
That is a significant shift. More than 27 percent of abortions in the first half of 2025 were provided via telehealth, and the ruling also blocks telemedicine prescriptions for miscarriage management, a point the drugmakers have emphasized in their filings.
Danco's filing painted a picture of immediate disruption. In its emergency request, the company warned that the ruling "injects immediate confusion and upheaval into highly time-sensitive medical decisions," forcing "providers, patients, and pharmacies all to guess at what is allowed and what is not."
The filing posed a pointed question to the justices:
"What happens when patients arrive for scheduled appointments this weekend... or walk into pharmacies... to obtain [the drug] that was prescribed... yesterday?"
Danco asked the court to issue an administrative stay right away and then block the ruling for a longer term while the case proceeds. The company also suggested the justices could take up the case on an expedited schedule before the end of the current term. As the Washington Times reported, Danco argued that Louisiana may lack legal standing to bring the case in the first place, an argument that could prove decisive if the justices engage with the merits.
GenBioPro CEO Evan Masingill framed the fight in broader terms. In a statement provided to Fox News Digital, Masingill said:
"The Supreme Court must reject this unfounded and baseless attack on an essential medication. GenBioPro firmly believes all people have a right to access safe, affordable, evidence-based health care, and we remain concerned that anti-abortion special interests are attempting to undermine the US Food and Drug Administration's regulatory authority. This is why we are bringing our fight to the Supreme Court."
GenBioPro's filing stated that the Fifth Circuit's order "eliminates nationwide access to mifepristone from certified pharmacies and by mail." The company is seeking a stay while the case moves through the courts.
Strip away the heated rhetoric and you find a genuinely important legal question. For years, the FDA loosened the rules around mifepristone, allowing telehealth prescriptions, mail delivery, and pharmacy dispensing, without the kind of rigorous public process that federal administrative law normally demands. The Fifth Circuit's ruling suggests those changes may not survive scrutiny under the Administrative Procedure Act.
That is not "chaos." That is a court doing its job, holding a federal agency to the procedural rules Congress wrote. The drugmakers and their political allies frame every legal setback as an emergency. But the emergency they describe is really just the return to rules that existed not long ago, before the FDA's deregulatory sprint during and after the pandemic.
As Just the News noted, Danco filed its emergency request on May 2, 2026, asking the justices to temporarily block the lower-court ruling while the appeal is under review. The federal appeals court decision would bar doctors from prescribing mifepristone via telehealth or sending it by mail, restoring the in-person safeguards that were standard practice before the FDA's recent changes.
Shawn Carney, president of 40 Days for Life, told Fox News Digital the emergency petition was no surprise. He pointed to the financial incentives driving the fight:
"Of course they filed an emergency petition. Big Pharma has gotten extremely rich after the unprecedented and radical deregulation of these dangerous abortion pills."
Carney went further, noting how recently the entire framework of mail-order abortion pills was created:
"No abortion advocate or anyone from Big Pharma was pushing to send these drugs through the mail just a few years ago, and now they act as if they're entitled to do so with zero regulation and zero oversight."
He added: "This is more evidence the FDA needs to reevaluate how these drugs were approved after years of ER visits from women who take them."
New York Attorney General Letitia James called the Fifth Circuit's decision "yet another cruel attack on abortion access" and declared that "mifepristone is safe, effective, and essential." Sen. Patty Murray said access to medication should not be decided by "judges without medical training."
The rhetoric is familiar. Every time a court applies the law in a way that inconveniences the abortion industry, Democratic officials describe it as an attack. But courts are not medical boards. Their job is to determine whether agencies followed the law, and the Fifth Circuit concluded the FDA likely did not.
This is not the first time the Supreme Court has been drawn into an emergency fight over mifepristone. In a previous round of litigation, the justices granted emergency requests from the Justice Department and Danco to pause lower-court restrictions, keeping the drug available nationwide while the case proceeded. Justices Clarence Thomas and Samuel Alito publicly dissented from that order. Alito wrote at the time that the administration and Danco "are not entitled to a stay because they have not shown that they are likely to suffer irreparable harm in the interim," as the Washington Free Beacon reported.
Whether Alito, who now holds the initial gatekeeping role for this latest filing, will act on his own or refer the matter to the full court remains an open question. The court could pause the ruling immediately, or it could let the Fifth Circuit's restrictions take effect nationwide while it considers the case.
The mifepristone fight fits a broader pattern at the Supreme Court, where politically charged cases increasingly arrive through the emergency docket. The justices have faced a string of high-stakes disputes in recent terms, from the earlier Fifth Circuit order blocking mifepristone by mail to redistricting battles and voting-rights cases that split the court along familiar lines.
Each time, the losing side accuses the justices of playing politics. Each time, the winning side insists the law is clear. The reality is that the administrative state has expanded so far, and agencies have taken so many shortcuts, that courts are now forced to referee disputes that Congress should have settled years ago.
The Court's recent unanimous decision backing a pro-life pregnancy center's right to fight a donor subpoena showed that the justices can find common ground on procedural questions even in politically sensitive territory. Whether they can do the same here, where the substantive stakes are higher and the political pressure is fiercer, is another matter entirely.
Mifepristone is one of two drugs commonly used in medication abortions. The legal battle over its distribution has become the central front in the post-Dobbs fight over abortion access, with pharmaceutical companies, state attorneys general, and advocacy groups on both sides treating every procedural ruling as an existential moment.
For pro-life advocates, the Fifth Circuit's ruling represents a long-overdue correction. The FDA relaxed safety requirements for a powerful drug under political pressure, and a federal court has now said those changes likely broke the rules. For the drugmakers, the ruling threatens a business model built on the assumption that telehealth and mail-order access would remain permanent.
The Supreme Court has handled several contentious cases from Louisiana's legal landscape in recent terms, and this latest dispute adds another layer to the Court's already crowded docket of politically sensitive emergency matters.
Justice Alito could act at any time. He could grant a temporary stay, deny the request, or refer it to the full court for consideration. Danco's suggestion that the justices take the case on an expedited schedule before the term ends adds urgency, but also raises the question of whether the Court wants to wade back into the mifepristone dispute so soon after its earlier intervention.
Several questions remain unanswered. Which specific FDA rules are at issue? Does Louisiana have standing to bring the case? And will the Court's conservative majority hold firm on the procedural principles that animated the Fifth Circuit's ruling, or will it bend under the political pressure that always accompanies abortion cases?
The Court's recent willingness to let lower-court orders stand in other high-profile cases suggests the justices are not automatically inclined to intervene every time an emergency filing lands on their desks. But mifepristone is different, the political temperature is higher, the industry lobby is louder, and the media coverage is relentless.
The drugmakers call it chaos. Pro-life advocates call it accountability. The Supreme Court will now decide which word applies, and whether the FDA can rewrite its own rules without following the law Congress laid down.
